A biotech R&D team found one supplier that would take on a modified peptide the rest of the market kept declining in pieces

Challenge

The team was building a research tool for a receptor-pharmacology question, and the peptide it needed combined several non-standard features at once — a non-natural residue, an intramolecular disulfide bridge, and an N-terminal cap. That combination is where most catalog SPPS shops tap out: the quotes the lab collected covered two of the modifications but balked at the third, or declined to attempt the non-natural residue together with the cyclization. The Head of Chemistry didn't want to split the molecule across vendors and reconcile mismatched documentation; the requirement was one supplier that would own the full modification stack and stand behind the identity evidence.

Approach

PeptideXpo confirmed the full modification stack sat inside our routine synthesis scope and scoped a pilot lot end to end — the non-natural building block, controlled oxidative folding favoring the intended intramolecular bridge over scrambled isomers, and N-terminal capping. The release documentation tied each modification back to a distinct, diagnostic mass shift, with tandem-MS sequence coverage across both arms of the bridged molecule, so the buyer's team could confirm the whole construct rather than infer it. Critically, all of it came from one supplier and one coherent documentation set, not three partial ones.

Outcome

The pilot lot arrived on a timeline that fit the research program, and the larger lot followed in parallel with the buyer's own pharmacology validation so the schedules overlapped. Because every modification mapped to its own diagnostic mass offset, the team took the material straight into pharmacology work without bolting on an extra identity-re-validation step. The route is now locked for repeat orders against a quarterly forecast.